Physician profile
William Rankine
NPI 1770540916
$475.74
in general payments reported to CMS, 2019-2025
11 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $135.28 | 2025 | Trintellix |
| Abbvie INC. | $70.19 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $54.54 | 2025 | Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.85 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.93 | 2025 | Jardiance |
| Pfizer INC. | $29.94 | 2025 | |
| Lilly USA, LLC | $25.37 | 2025 | Zepbound |
| Novo Nordisk INC | $20.95 | 2025 | Ozempic |
| Abbott Laboratories | $20.84 | 2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $17.56 | 2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $17.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rankine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.